{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:08:17Z","timestamp":1780988897580,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent ischemic priapism (RIP) is a repetitive, self-remitting subtype of ischemic priapism with high risk of progression to major ischemic priapism (MIP), which can cause irreversible fibrosis and erectile dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To identify the risk factors for MIP in patients with RIP and develop a prognostic model and a RIP severity scoring system to predict future MIP events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review of patients with RIP across a major academic health system (May 2006\u2013November 2020). Demographic, clinical, and priapism characteristics were collected, and univariate and multivariable Poisson regression analyses were performed to identify predictors of MIP events per person-year (MIP PPY). Internal validation was performed using 10-fold cross-validation with mean absolute error as the performance metric. A web-based dynamic nomogram was created from significant risk factors, and patients were risk-stratified based on predicted MIP PPY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Primary outcome was the incidence rate ratio of MIP PPY predicted by significant risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 113 patients (mean age 32\u00a0years, mean follow-up 3\u00a0years), 225 MIP events were recorded over 557.5 person-years. Multivariable analysis identified longer priapism duration, adult-onset RIP (&amp;gt;25\u00a0years old), sickle cell disease, marijuana use, and tobacco smoking as independent predictors of increased MIP PPY. Patients were classified post hoc as low-risk (&amp;lt;1 MIP PPY, n\u2009=\u200981) or high-risk (\u22651 MIP PPY, n\u2009=\u200932), with high-risk patients exhibiting longer priapism episodes, older age of onset, and higher recurrence rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>The nomogram offers an investigational tool for individualized risk estimation that, if validated, may help identify patients at higher risk of MIP and inform future study of preventive strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and limitations<\/jats:title>\n                    <jats:p>Strengths include the largest RIP cohort reported to date, robust statistical modeling, and creation of an interactive nomogram. Limitations include retrospective single-institution design, potential underreporting of priapism events, and lack of external validation, which may limit generalizability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies key MIP risk factors in patients with RIP, introduces a novel dynamic nomogram to predict future MIP events, and proposes a RIP severity scoring system that may improve risk stratification, inform treatment decisions, and guide future prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag167","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:30Z","timestamp":1778760450000},"source":"Crossref","is-referenced-by-count":0,"title":["Predicting major ischemic priapism: a novel dynamic nomogram based on recurrent ischemic priapism risk factors"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-7378","authenticated-orcid":false,"given":"Laurence T","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Urology, Hackensack University Medical Center , Hackensack, NJ 07601 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezhou","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J","family":"Trock","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-8605","authenticated-orcid":false,"given":"Arthur L","family":"Burnett","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine , Baltimore, MD 21287,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"2026060902535698600_ref1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/JU.0000000000002767","article-title":"The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA\/SMSNA guideline","volume":"208","author":"Bivalacqua","year":"2022","journal-title":"J Urol"},{"issue":"9","key":"2026060902535698600_ref2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1464-410x.2002.03022.x","article-title":"Priapism in sickle-cell disease; incidence, risk factors and complications\u2014an international multicentre study","volume":"90","author":"Adeyoju","year":"2002","journal-title":"BJU Int"},{"issue":"6","key":"2026060902535698600_ref3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bjh.12199","article-title":"How I manage priapism due to sickle cell disease","volume":"160","author":"Olujohungbe","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"2026060902535698600_ref4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/archinte.1980.00330220022011","article-title":"Priapism and impotence in homozygous sickle cell disease","volume":"140","author":"Emond","year":"1980","journal-title":"Arch Intern Med"},{"key":"2026060902535698600_ref5","author":"Centers for Disease Control and Prevention"},{"issue":"9861","key":"2026060902535698600_ref6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet."},{"issue":"1","key":"2026060902535698600_ref7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MPH.0000000000002056","article-title":"Psychometric impact of priapism on lives of adolescents and adults with sickle cell Anemia: a sequential independent mixed-methods design","volume":"44","author":"Idris","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"2026060902535698600_ref8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/jsm.12816","article-title":"Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors","volume":"12","author":"Anele","year":"2015","journal-title":"J Sex Med"},{"issue":"4","key":"2026060902535698600_ref9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.sxmr.2022.06.007","article-title":"Priapism or prolonged erection: is 4-6 hours of cavernous ischemia the time point of irreversible tissue injury?","volume":"10","author":"Dekalo","year":"2022","journal-title":"Sex Med Rev"},{"issue":"1","key":"2026060902535698600_ref10","first-page":"9","article-title":"Pharmacologic erection: time-dependent changes in the corporal environment","volume":"6","author":"Broderick","year":"1994","journal-title":"Int J Impot Res"},{"issue":"6","key":"2026060902535698600_ref11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.eururo.2008.09.044","article-title":"The immediate insertion of a penile prosthesis for acute ischaemic priapism","volume":"56","author":"Ralph","year":"2009","journal-title":"Eur Urol"},{"issue":"1","key":"2026060902535698600_ref12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1743-6109.2004.10117.x","article-title":"Priapism","volume":"1","author":"Pryor","year":"2004","journal-title":"J Sex Med"},{"issue":"2","key":"2026060902535698600_ref13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/JU.0000000000001365","article-title":"Regimented phosphodiesterase type 5 inhibitor use reduces emergency department visits for recurrent ischemic priapism","volume":"205","author":"Hou","year":"2021","journal-title":"J Urol"},{"issue":"7","key":"2026060902535698600_ref14","doi-asserted-by":"publisher","first-page":"e68028","DOI":"10.1371\/journal.pone.0068028","article-title":"Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative\/nitrosative stress","volume":"8","author":"Bivalacqua","year":"2013","journal-title":"PLoS One"},{"issue":"31","key":"2026060902535698600_ref15","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.2174\/138161205774913381","article-title":"The nitric oxide signaling pathway in the penis","volume":"11","author":"Burnett","year":"2005","journal-title":"Curr Pharm Des"},{"issue":"5","key":"2026060902535698600_ref16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bju.15370","article-title":"Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm","volume":"127","author":"Joice","year":"2021","journal-title":"BJU Int"},{"issue":"3","key":"2026060902535698600_ref17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1046\/j.1464-4096.2001.01510.x","article-title":"Low-flow priapism: risk factors for erectile dysfunction","volume":"89","author":"El-Bahnasawy","year":"2002","journal-title":"BJU Int"},{"issue":"6 Pt. 1","key":"2026060902535698600_ref18","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/S0022-5347(01)62307-3","article-title":"Expression of TGF-beta-1 mRNA and ultrastructural alterations in pharmacologically induced prolonged penile erection in a canine model","volume":"160","author":"Ul-Hasan","year":"1998","journal-title":"J Urol"},{"key":"2026060902535698600_ref19","volume-title":"Springer","author":"","year":"2021"},{"key":"2026060902535698600_ref20","first-page":"440","volume-title":"Forecasting: Principles and Practice","author":"Hyndman","year":"2021","edition":"Third print"},{"key":"2026060902535698600_ref21","first-page":"1","volume-title":"Applied Predictive Modeling. Corrected at 5th Printing","author":"Kuhn","year":"2016"},{"issue":"11","key":"2026060902535698600_ref22","doi-asserted-by":"publisher","first-page":"e0225253","DOI":"10.1371\/journal.pone.0225253","article-title":"Visualising statistical models using dynamic nomograms","volume":"14","author":"Jalali","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"2026060902535698600_ref23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.urology.2005.11.045","article-title":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","volume":"67","author":"Burnett","year":"2006","journal-title":"Urology."},{"issue":"6","key":"2026060902535698600_ref24","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/j.1743-6109.2006.00333.x","article-title":"Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism","volume":"3","author":"Burnett","year":"2006","journal-title":"J Sex Med"},{"issue":"1","key":"2026060902535698600_ref25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s0022-5347(17)34928-5","article-title":"Anoxia and corporal smooth muscle dysfunction: a model for ischemic priapism","volume":"151","author":"Broderick","year":"1994","journal-title":"J Urol"},{"issue":"20","key":"2026060902535698600_ref27","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1182\/bloodadvances.2022007285","article-title":"Incidence and predictors of priapism events in sickle cell anemia: a diary-based analysis","volume":"6","author":"Idris","year":"2022","journal-title":"Blood Adv"},{"key":"2026060902535698600_ref28","doi-asserted-by":"publisher","first-page":"193694","DOI":"10.1155\/2008\/193694","article-title":"Priapism, ecs,tasy, and marijuana: is there a connection?","volume":"2008","author":"Tran","year":"2008","journal-title":"Adv Urol"},{"issue":"1","key":"2026060902535698600_ref29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s42238-020-0015-8","article-title":"Recurrent priapism in the setting of cannabis use","volume":"2","author":"Montgomery","year":"2020","journal-title":"J Cannabis Res"},{"issue":"5","key":"2026060902535698600_ref30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.encep.2020.09.003","article-title":"Priapism and cannabism: a case report and review of the literature","volume":"47","author":"Chouaib","year":"2021","journal-title":"Encephale."},{"key":"2026060902535698600_ref31","first-page":"1539","volume-title":"Campbell Walsh Wein Urology","author":"Partin","year":"2020","edition":"12th"},{"issue":"4","key":"2026060902535698600_ref32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.sxmr.2016.05.001","article-title":"Male sexual function and smoking","volume":"4","author":"Biebel","year":"2016","journal-title":"Sex Med Rev"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag167\/68486520\/qdag167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/7\/qdag167\/68486520\/qdag167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:54:04Z","timestamp":1780988044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag167\/8703588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag167","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,5]]},"article-number":"qdag167"}}